

PROGRAM SEMMERING VACCINE SYMPOSIUM 2011

Semmering V: Vaccines – The key paradigm for the 21st century's health care strategy

THURSDAY, APRIL 28, 2011

OPENING AND KEY NOTE LECTURE

15.00-15.40 Welcome address: Alexander von Gabain, MFPL of the University of Vienna, Chair of the SAB of Intercell, Vienna, Austria
Key note speaker: **Martin Schuurmans**, European Institute of Innovation and Technology (EIT)
EIT: Create ecosystems that nurture new business creation for Europe

15.40-16:00 *Coffee break*

SESSION 1: Badly needed novel vaccines (Chair: Alexander von Gabain)

16:00-16:20 **Franz Xaver Heinz**, University of Vienna, Institute of Virology, Vienna, Austria
Flaviviruses

16:20-16:40 **Ginamarie Foglia**, Sanofi Pasteur, Swiftwater, USA
C difficile

16:40-17:00 **Peter Lawætt Andersen**, Statens Serum Institut, Copenhagen, Denmark
TB program

17:00-17:20 **Wayne C. Koff**, International AIDS Vaccine Initiative, New York, USA
Challenges and opportunities in HIV vaccine development

17:20-18:00 Challenge panel:

Michael Pfleiderer, Paul Ehrlich Institute, Langen, Germany

Andrew Baum, Morgan Stanley & Co. International Limited, London, UK

OPENING POSTER SESSION AND GET TOGETHER

18:00-19:00 Opening POSTER SESSION

19:00 Dinner

FRIDAY, APRIL 29, 2011

SESSION 2: What vaccinologists expect from immunologists (Chair: Thomas Decker)

08:30-08:50 **Richard Malley**, Harvard Medical School, Children's Hospital, Boston, USA
Role of TH17 in the pneumococcal immune response

08:50-09:10 **Giorgio Trinchieri**, National Cancer Institute at Frederick, Frederick, USA
Regulation of adaptive immunity by NK cells

09:10-09:30 **Jay A. Berzofsky**, National Cancer Institute, Bethesda, USA
TLR ligands, cytokines, and the T cell response

09:30-09:50 **Georg Stingl**, General Hospital Vienna, Vienna, Austria
Different DCs - different functions

09:50-10:30 Challenge panel:

Michael Pride, Pfizer Inc., Pearl River, New York, USA

Rino Rappuoli, Novartis Vaccines, Siena, Italy

Thomas Decker, Max F. Perutz Laboratories, Vienna, Austria

10:30-11:00 *Morning break*

SESSION 3: About allergies, autoimmunity, microbes and vaccines (Chair: Eszter Nagy)

- 11:00-11:20 **Andrew T. Gewirtz**, Emory University, School of Medicine, Atlanta, USA
Innate immune regulation of gut microbiota and potential therapeutic opportunities to treat metabolic disease and chronic infections
- 11:20-11:40 **Brigit Linhart** Medical University of Vienna, Vienna, Austria
A vaccine for the treatment of grass pollen allergy based on hypoallergenic hybrid molecules
- 11:40-12:00 **Bengt Björkstén**, Karolinska Institute, Stockholm, Sweden
The Hygiene Hypothesis; Consequences for vaccine development
- 12:00-12:20 **Peter Zerhouni**, Diamyd Medicals, Stockholm, Sweden
A diabetes vaccine
- 12:20-13:00 Challenge panel:
Hans Wigzell, Karolinska Institute, Stockholm, Sweden
Philippe Moingeon, Stallergenes S.A., Antony Cedex, France

13:00-14:30 *Lunch break*

SESSION 4: Novel adjuvants - breakthroughs and setbacks, where will we end? (Chair: Sefik S. Alkan)

- 14:30-14:50 **Hermann Wagner**, Technical University Munich, München, Germany
Adjuvants and innate immunity
- 14:50-15:10 **Ozzie Berger**, GlaxoSmithKline Biologicals, Wavre, Belgium
TLR-4: From research to registered vaccines
- 15:10-15:30 **Derek O´Hagan**, Novartis Vaccine and Diagnostics, Cambridge, USA
MF59
- 15:30-15:50 **Veit Hornung**, University Hospital Bonn, Bonn, Germany
Role of the inflammasome in adjuvanticity
- 15:50-16:10 **Claire-Ann Siegrist**, University of Geneva, Geneva, Switzerland
Neonatal immunization: which challenges for novel vaccines?
- 16:10-16:50 Challenge panel:
Steven G. Reed, IDRI - Infectious Disease Research Institute, Seattle, USA
Martin Friede, World Health Organization, Geneva, Switzerland
Sefik S. Alkan, Alkan Consulting LLC, Basel, Switzerland

16:50-18:30 *Long afternoon break*

AUSTRIAN EVENING

- 18:30-19:15 **In the footsteps of *The Third Man* - A cinematic and musical journey through Vienna**
Rare and unusual filmic views of Vienna - presented by Michael Loebenstein
Famous Viennese zithermusic live and authentic in style - played by Cornelia
- 19:30- **Dinner** - Buffet with traditional Austrian food and live-cooking of “Kaiserschmarren” (Austrian dessert)

SATURDAY, APRIL 30, 2011

SESSION 5: Improving administration also for vaccines in the less developed world (Chair: *Maria Elena Bottazzi*)

- 08:30-08:50 **Larry Ellingsworth**, Intercell USA, Gaithersburg, USA
Patch technology
- 08:50-09:10 **Martine Denis**, Sanofi Pasteur, Marcy l'Etoile, France
*Microneedle technology and its application to influenza vaccination by the
intradermal route*
- 09:10-09:30 **Michael Royals**, PharmaJet, Golden, Colorado, USA
Enhancing vaccination outcomes with an ID jet injection device
- 09:30-09:50 **Georg Mutwiri**, University of Saskatchewan, Saskatoon, Canada
PCPP-based microneedles
- 09:50-10:30 Challenge panel:

Maria Elena Bottazzi, The George Washington University, Washington, USA
Andreas Meinke, Intercell AG, Vienna, Austria
Christoph Klade, Intercell AG, Vienna, Austria

10:30-11:00 Morning break

SESSION 6: Quo vadis flu vaccines - learning from the H1N1 pandemic in the light of new technologies and established paradigms (Chair: *Geert Vanden Bossche*)

- 11:00-11:20 **Lone Simonsen**, The George Washington University, Washington, USA
Signature features and health burden of the 2009 H1N1 pandemic and historic pandemics
- 11:20-11:40 **Klaus Stöhr**, Novartis Vaccines and Diagnostics, Cambridge, USA
Novel influenza vaccines: how will they meet health needs
- 11:40-12:00 **Derek Smith**, University of Cambridge, UK
The antigenic evolution of influenza virus
- 12:00-12:20 **Gerald Aichinger**, Baxter Innovations GmbH, Vienna, Austria
A cell culture flu vaccine
- 12:20-12:40 **Thomas Hofstaetter**, VaxInnate, Cranbury, USA
A simple approach to a flu vaccine
- 12:40-13:20 Challenge panel:

John Oxford, Queen Mary School of Medicine, London, UK
Michael Perdue, U.S. Department of Health & Human Services, Washington, USA

13:20-15:00 Lunch break

SESSION 7: Late breakers in vaccine development (Chair: Gerd Zettlmeissl)

- 15:00-15:20 **Jessica Flechtner**, Genocea Biosciences, Cambridge, USA
T cell vaccines
- 15:20-15:40 **Michael Wacker**, GlycoVaxyn AG, Schlieren, Switzerland
Paradigm shift in discovery and production of glycoconjugate vaccines
- 15:40-16:00 **Robert Sims**, Dendreon Corporation, Seattle, USA
Sipuleucel-T: Autologous cellular immunotherapy for prostate cancer
- 16:00-16:20 **Maria Elena Bottazzi**, The George Washington University, Washington, USA
Advances in the development of vaccines against neglected tropical diseases
- 16:20-16:40 **Karl-Josef (“Kajo”) Kallen**, CureVac GmbH, Tübingen, Germany
Messenger RNA-based vaccines: a new approach to immunization
- 16:40-17:00 *Afternoon break*

CONCLUDING PANEL DISCUSSION: Need and acceptance of vaccines - how to deal with it?
Panel on the importance of vaccines for global health care and how to deal with fear

- 17:00-18:00 **Stanley Plotkin**, Consultant in Vaccinology, Doylestown, USA
Fred Zepp, Johannes Gutenberg University of Mainz, Germany
John Shiver, Merck & Co., Inc., West Point, USA
Thomas Szucs, European Center of Pharmaceutical Medicine, University of Basel, Switzerland
Shan Lu, University of Massachusetts Medical School, Worcester, USA
Chairman: Alexander von Gabain, MFPL of the University of Vienna, Chair of the SAB of Intercell, Vienna, Austria

19:00 - ... **CLOSING DINNER**

The Semmering Symposium 2011 is held under the auspice of the Royal Swedish Academy of Engineering Sciences, IVA, and co-sponsored by The Elsevier journal Vaccine, Intercell AG, CureVac GmbH and Bank of America Merrill Lynch:

